Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABO2203 in Relapsed or Refractory B-NHL
NCT07072169Phase 1Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2025
- Primary completion
- Jun 2026
- Modality
- Bispecific Antibodies, RNA Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ABO2203 in B-cell non-Hodgkin lymphoma, sponsored by Ruijin Hospital. Primary endpoint: Safety, Tolerability, and Preliminary Efficacy. Started May 2025; status: recruiting.
02
Drugs
ABO2203
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07072169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072169.